Research progress in corneal cross-linking agents

Area of Science:

• Ophthalmology
• Biomaterials Science
• Corneal Disease Research

Background:

• Keratoconus progression is currently only preventable via UVA-riboflavin corneal collagen cross-linking.
• Topical cross-linking agents are gaining clinical interest for treating corneal diseases.

Purpose of the Study:

• To review research on indirect and direct cross-linking agents for corneal disease treatment.
• To analyze the efficacy, toxicity, and comparative advantages/disadvantages of various cross-linking agents.

Main Methods:

• Literature review of studies on corneal cross-linking agents.
• Analysis of cross-linking efficacy, toxicity, and clinical merits/demerits.
• Inclusion of agents like riboflavin, glucose, ribose, glutaraldehyde, formaldehyde, glyceraldehyde, short chain aliphatic β-nitro alcohol, and genipin.

Main Results:

• UVA-riboflavin is the established standard for keratoconus.
• Various agents show potential but require further investigation regarding efficacy and safety profiles.
• Comparative analysis highlights specific strengths and weaknesses of each agent.

Conclusions:

• Cross-linking agents offer promising therapeutic avenues for corneal diseases beyond keratoconus.
• Further research is needed to optimize agent selection and application protocols for clinical use.
• This review provides essential data for guiding future clinical studies and therapeutic development.